Teleflex (TFX) Stock News

Teleflex (NYSE: TFX) announced that Chairman, President and CEO Liam Kelly will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 9:30 a.m. GMT. The presentation will be accessible via live audio webcast through the investor section of the Teleflex website at teleflex.com.

Teleflex (NYSE: TFX) has announced a quarterly cash dividend of $0.34 per share of common stock. The dividend will be paid on December 16, 2024, to shareholders who are on record as of the close of business on November 15, 2024.

Teleflex (TFX) reported Q3 2024 financial results with GAAP revenue of $764.4 million, up 2.4% year-over-year. The company lowered its full-year 2024 GAAP revenue growth guidance to 2.90%-3.40% from previous 3.40%-4.40%. GAAP diluted EPS from continuing operations was $2.36, compared to $2.91 in prior year. Adjusted diluted EPS was $3.49 versus $3.64 last year. Strong performances in Interventional and Vascular Access segments helped offset weakness in OEM revenues. The company announced a $500 million share repurchase authorization, including a $200 million accelerated share program in Q3.

Teleflex (NYSE: TFX) announced enrollment of the first patient in the PPRT Trial, a randomized controlled study evaluating the Barrigel™ rectal spacer in patients undergoing radiation therapy after prostatectomy. The study aims to demonstrate the safety and effectiveness of Barrigel™, the first sculptable hyaluronic acid rectal spacer, in reducing radiation side effects.

The trial will be conducted across sites in the U.S. and Australia, focusing on patients who have undergone nerve-sparing prostatectomy with no evidence of metastatic disease. Barrigel™'s unique properties allow physicians to sculpt and optimize rectal protection during radiation therapy, remaining soft and pliable unlike other spacers that harden immediately after administration.

Teleflex Incorporated (NYSE: TFX) presented data at ASTRO 2024 supporting the safety and efficacy of Barrigel™ rectal spacer, the first sculptable hyaluronic acid rectal spacer for prostate cancer radiation therapy. Key findings include:

1. High-quality rectal spacing with low rectal dose and excellent toxicity profile
2. Low incidence (0.32-1%) of rectal wall infiltration (RWI), reversible with hyaluronidase
3. Efficacy in stereotactic body radiation therapy (SBRT) for repeat therapy patients

The data demonstrate Barrigel's advantages over other rectal spacers, including its sculptability and reversibility. Three abstracts presented real-world evidence of Barrigel's performance, showing excellent implant quality, symmetrical spacing, and low toxicity rates. The spacer also proved effective in patients undergoing repeat radiation therapy.

Teleflex Incorporated (NYSE:TFX) has announced its upcoming third quarter 2024 earnings conference call, scheduled for Thursday, October 31, 2024, at 8:00 a.m. Eastern Time. The call will provide an opportunity for the company to discuss its financial results and offer an operational update. Interested participants can pre-register to receive dial-in information. Additionally, a live audio webcast will be available on the Teleflex website.

For those unable to attend the live call, an audio replay will be accessible starting at 11:00 am Eastern Time on the same day. The replay can be accessed via the Teleflex website or by phone using the provided dial-in numbers and conference ID.

Teleflex Incorporated (NYSE: TFX) announced that three clinical studies on its Barrigel™ rectal spacer will be presented at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. The studies focus on the safety and efficacy of Barrigel™, the first commercial hyaluronic acid rectal spacer designed to protect the rectum during prostate cancer radiation therapy.

Key presentations include:

• Impact of Hyaluronic Acid Rectal Spacer Quality Score on rectal dosimetry and toxicity outcomes
• Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol
• Hyaluronic Acid Rectal Spacer use in locally recurrent prostate cancer patients

Teleflex will also host an educational symposium on 'The Science of Personalized Spacing' and showcase the Barrigel™ procedure at their booth during the event.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has chosen o9's AI-powered platform to enhance its end-to-end integrated business planning and supply chain management capabilities. The partnership includes o9's Demand Planning, Supply Planning, and Integrated Business Planning (IBP) technologies.

Teleflex, headquartered in Wayne, Pennsylvania, offers a diverse portfolio of solutions in anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company aims to improve the health and quality of people's lives and become the most trusted partner in healthcare.

David Clarke, Vice President of Demand Fulfilment at Teleflex, expressed confidence in o9's ability to handle their complex supply chain requirements and help achieve strategic objectives. o9's platform is expected to enhance supply chain efficiency, optimize inventory, and empower Teleflex's workforce through improved processes and technology.

Teleflex (NYSE: TFX) announced that its Chairman, President and CEO, Liam Kelly, will be speaking at the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Friday, September 6, 2024, at 7:45 a.m. (ET) and will take place at the Marriott Marquis New York.

Investors and interested parties can access a live audio webcast of the conference presentation through the investor section of the Teleflex website. This presentation offers an opportunity for stakeholders to gain insights into Teleflex's current position and future strategies in the healthcare industry.